Forbion Growth III added three new companies in Q2, all with high clinical relevance and strong market potential. CellCentric (UK) develops an oral treatment for recurrent, therapy-resistant blood cancers aimed at restoring response to existing therapies. Azafaros (NL) focuses on rare neurological diseases in children and young adults, with its therapy intended to slow disease progression. Sparrow (US) is developing a pill that lowers cortisol levels and can improve blood sugar control in a subset of type 2 diabetes patients, with potentially beneficial effects on weight and blood pressure.
Through these additions, the fund broadens its portfolio and builds value in therapeutic areas with limited competition and significant unmet medical need.